Bristol-Myers Squibb On Sunday Announced Empliciti (elotuzumab) Plus Pomalidomide And Low-Dose Dexamethasone Reduces Risk Of Disease Progression By 46% Versus Pomalidomide/Dexamethasone Alone In Patients With Relapsed Or Refractory Multiple Myeloma